IRVINE, Calif.--(BUSINESS WIRE)--

Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq: OCUL). Investors who purchased or otherwise acquired shares between May 5, 2017 and July 6, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the September 5, 2017 lead plaintiff motion deadline.

If you purchased Ocular shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company’s management has been misleading investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product; that such manufacturing issues could endanger the approval of DEXTENZA by the Food and Drug Administration; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this information was announced, shares of Ocular declined in value materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170710006408/en/